Holen Sie sich die Stockscreener-App
87.78
0.76%
-0.60
Handel nachbörslich:
87.76
-0.02
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$88.38
Offen:
$88.6
24-Stunden-Volumen:
6.49M
Relative Volume:
0.55
Marktkapitalisierung:
$152.86B
Einnahmen:
$45.13B
Nettoeinkommen (Verlust:
$6.28B
KGV:
24.45
EPS:
3.5895
Netto-Cashflow:
$7.38B
1W Leistung:
+3.31%
1M Leistung:
-5.41%
6M Leistung:
-31.54%
1J Leistung:
-34.08%
1-Tages-Spanne:
$86.83
$88.60
1-Wochen-Bereich:
$84.13
$89.34
52-Wochen-Spanne:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
87.76 | 153.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.46 | 123.25B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.13 | 84.23B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.20 | 47.77B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Buying pulsed field ablation systems: What hospitals should know - Modern Healthcare News
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence - GlobeNewswire Inc.
Abbott Laboratories stock (US0028241000): diabetes business and latest earnings in focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): investors eye upcoming Q4 2025 earnings call and biosimila - AD HOC NEWS
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum - TradingView
Abbott Laboratories stock (US0028241000): steady medical devices player after latest quarterly updat - AD HOC NEWS
Worker says Abbott fired him over a chat his coworker started - hcamag.com
ECMC debuts new high-tech blood & urine lab to cut down on processing times by 20 percent - WKBW
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Spinal Cord Stimulator Problems Resulted in Severe Paralysis: Lawsuit - AboutLawsuits.com
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $109 - 富途牛牛
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings - Yahoo Finance
Abbott Laboratories stock (US0028241000): steady momentum after latest earnings and diabetes tech pu - AD HOC NEWS
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity? - simplywall.st
Build-A-Bear Workshop and Abbott Laboratories o... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
A Look at Abbott Laboratories (ABT) After 4.1% Gain -- GF Value $127.69 vs Price $87.91 - GuruFocus
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know - TradingKey
Boston Scientific Bets on Growth Through Strategic M&A Deals - TradingView
Raised full-year 2026 outlook lifts Abbott stock 3.18% - Traders Union
Abbott Laboratories (ABT) is attracting investor attention: Here is what you should know - MSN
Trump’s stock trading spree included North Chicago’s Abbott Labs - Crain's Chicago Business
Abbott stock posts modest gain amid fragile momentum below MA-20 resistance: weekly review - Traders Union
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? - TradingView
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Thrivent Financial for Lutherans Acquires 48,286 Shares of Abbott Laboratories $ABT - MarketBeat
North Dakota State Investment Board Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) Stock Analysis: Unlocking a 40% Potential Upside for Savvy Investors - DirectorsTalk Interviews
Abbott Laboratories $ABT Shares Purchased by Cambridge Investment Research Advisors Inc. - MarketBeat
Abbott Laboratories stock (US0028241000): Q1 2026 growth, guidance raise and diabetes momentum - AD HOC NEWS
Abbott Laboratories stock (US0028241000): diabetes growth and fresh guidance keep investors focused - AD HOC NEWS
Abbott Laboratories Stock (ABT) Opinions on Recent Price Declines - Quiver Quantitative
Abbott Laboratories stock (US0028241000): diabetes segment drives attention after latest quarterly u - AD HOC NEWS
Abbott Laboratories $ABT Stock Holdings Lowered by iA Global Asset Management Inc. - MarketBeat
AlphaCore Capital LLC Increases Stock Position in Abbott Laboratories $ABT - MarketBeat
Abacus Wealth Partners LLC Buys 12,260 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Trade Ideas — LSX:850103 - TradingView
Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment - simplywall.st
Commerzbank Aktiengesellschaft FI Sells 131,572 Shares of Abbott Laboratories $ABT - MarketBeat
Bessemer Group Inc. Sells 213,665 Shares of Abbott Laboratories $ABT - MarketBeat
ABT (NYSE: ABT) Form 144 shows 7,587 RSU shares and prior 29,211 sale - Stock Titan
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
Is the options market predicting a spike in Abbott Laboratories stock? - MSN
Abbott Laboratories stock (US0028241000): Q1 beat, Exact Sciences deal and legal risks keep investor - AD HOC NEWS
Abbott class action alleges FreeStyle Libre 2 glucose monitor is defective - Class Action Lawsuits
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up - Yahoo Finance
Phoenix Financial Ltd. Increases Stock Position in Abbott Laboratories $ABT - MarketBeat
Summit Wealth Group LLC Co. Sells 21,449 Shares of Abbott Laboratories $ABT - MarketBeat
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abbott Laboratories-Aktie (ABT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
2.28%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):